- Home
- RVMD vs ES Comparison
RVMD vs ES Comparison
Compare RVMD & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVMD | ES |
|---|---|---|
| Founded | 2014 | 1927 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 25.1B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | RVMD | ES |
|---|---|---|
| Price | $154.30 | $68.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 11 |
| Target Price | ★ $140.84 | $71.00 |
| AVG Volume (30 Days) | 2.0M | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.58% |
| EPS Growth | N/A | ★ 100.88 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $13,547,244,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $533.02 | $3.77 |
| P/E Ratio | ★ N/A | $43.01 |
| Revenue Growth | N/A | ★ 13.83 |
| 52 Week Low | $34.00 | $61.53 |
| 52 Week High | $156.25 | $76.41 |
Technical Indicators
Market Signals| Indicator | RVMD | ES |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 49.09 |
| Support Level | $93.39 | $66.53 |
| Resistance Level | N/A | $68.84 |
| Average True Range (ATR) | 5.02 | 1.22 |
| MACD | -0.50 | 0.13 |
| Stochastic Oscillator | 81.16 | 53.71 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.